Biogen (Nasdaq: BIIB) has agreed to acquire San Diego-based RayThera Inc. for up to USD 1 billion, adding a portfolio of small molecule anti-inflammatory assets to its US-based immunology pipeline. The deal reflects Biogen's accelerating strategy of using M&A to build out its immunology franchise beyond its neuroscience heritage, with the lead RayThera candidate expected to enter Phase I development in early Q3 2026.
Under the terms of the definitive agreement, Biogen will make an undisclosed upfront cash payment to RayThera's shareholders, who remain eligible for clinical and regulatory milestone payments that constitute the predominant share of the total potential consideration of up to USD 1 billion. No royalty terms were disclosed. Biogen will assume full responsibility for global development, manufacturing, and commercialization upon closing, which is anticipated in Q3 2026, subject to customary regulatory approvals. RayThera completed a Series A financing for USD 110 million in April 2025, co-led by Foresite Capital and OrbiMed Advisors.
RayThera's portfolio comprises multiple anti-inflammatory small molecules designed to treat immune-mediated conditions across a range of indications. Specific targets and mechanisms of action were not disclosed in the announcement. The lead candidate is described as poised to enter Phase I, positioning it as an early-stage asset with significant binary clinical risk — a profile consistent with the milestone-heavy, upfront-light deal structure. No clinical trial registrations for RayThera's programs were publicly available at the time of announcement, consistent with the company's pre-IND or IND-enabling stage.